Aurobindo Pharma arm pulled up by USFDA over manufacturing lapses at Telangana plant

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-08-26T14:30:12+05:30 | Updated On 26 Aug 2024 2:30 PM IST

New Delhi: Aurobindo Pharma's subsidiary Eugia has been pulled up by the US Food and Drug Administration (USFDA) over manufacturing lapses at its Telangana-based plant. In a warning letter addressed to Eugia Pharma Specialities' CEO, Yugandhar Puvvala, the regulatory body highlighted the company's failure to ensure the accuracy of data related to production and process simulation.

USFDA inspected your drug manufacturing facility, Eugia Pharma Specialities Limited (Unit III), FEI 3008461619, at Plot No.: 4, 34 to 48, EPIP, TSIIC, IDA-Pashamylaram, Patancheru (Mandal), Sangareddy, Hyderabad, Telangana, from January 22 to February 2, 2024.

"Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards," USFDA stated.

"You failed to ensure the accuracy of data in records for both production and process simulations (media fills)," USFDA noted.

Your operators also falsified environmental monitoring records for the ISO 5 and ISO 7 areas of multiple aseptic filling lines, including for viable active air samples and non-viable particle counts which were not collected in their documented location, it added.

The USFDA also stated that the company failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug products produced.

"You failed to ensure records for equipment cleaning, disinfection, and sterilisation are complete and accurate," the latter noted.

According to PTI, Aurobindo Pharma spokesperson said, "There is no impact on the existing supplies to the US markets."

The company remains committed to work closely with the US FDA and continues to enhance its compliance on an ongoing basis, the spokesperson added.

According to USFDA, the company also failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes.

The warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, it said.

A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations.

USFDA sought a detailed corrective action plan that describes how the company intends to ensure the reliability and completeness of all the data generated including analytical data and manufacturing records.

The letter also sought a comprehensive description of the root causes of data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment.

"FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any deviations," USFDA said.

It further stated: "After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence."

The warning letter issued by the USFDA usually identifies the violation, such as poor manufacturing practices, problems with claims for what a product can do, or incorrect directions for use.

The letter also makes clear that the company must correct the problem and provide directions and a timeframe of its plans for correction.

FDA then checks to ensure that the company's corrections are adequate.

aurobindo pharmaaurobindo pharma newsEugia Pharma SpecialitiesUSFDA

Source : with inputs

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751